Herlig at noen kan tjene på at Atlas på død og liv skal ut raskest mulig uten å ha lengre briller på enn to dager om gangen.
1 Like
Det har vært eneste måte å tjene penger på i dette selskapet, såfremt du ikke er utenforstående som får mye penger for å garantere for emi.
De har kanskje skiftet navn, men det er fortsatt samme folkene, så å forvente at de skal endre seg på det punktet er nok å be om for meget.
~490.000 aktier til 0,78 viser, at der stadigvæk er interesserede i markedet, og dét med god grund, efter min mening, særligt når man tænker på de massive udfordringer som i angiveligt konkurrerende LaRonde står i.
Men aktien bevæger sig mod 1,00 og står overfor et modstandsniveau, der potentielt er blevet cementeret siden juni '22 og et brug gennem dette niveau må betragtes som værende et massivt signal … ved et brud på 0,8, så hedder næste stop 1,00.
Selskabet signalerer, at aktionærerne bør følge med på morgendagens opdatering og jeg garanterer, at jeg personligt vil sidde klar.
1 Like
Hvis jeg forstår vilkårene rett så er Atlas sin mulighet til å konvertere aksjer basert på prisingen de siste tre dagers VWAP. Nå begynner den å bli vesentlig høyere enn sist gang.
Er ikke hele konseptet riv ruskende galt hvis dødsspiralen skal begynne å stige?? 
The convertible bonds will be issued at 92 percent of nominal value and thereby provide Targovax with a total of up to NOK 276 million in net capital. The bonds will not carry any interest and can be converted into shares at the discretion of Atlas, at a price determined as 100 percent of the average volume weighted share price (VWAP) of three of the last 15 trading days preceding the bond conversion request by Atlas. After conversion, Atlas may sell the Targovax shares in the market subject to certain pre-defined restrictions. Targovax retains the right to repurchase unconverted bonds at any time at 110 percent of nominal value.
Ikke helt umulig?
Ikke helt rett. De kan velge 3 dager blant de siste 15 handelsdagene. Noe som gir de gode muligheter til å veksle inn til aksjer rundt 0,5 en stund til. Så bli ikke overrasket om det plutslig blir trykket opp et titalls millioner aksjer klare til å bli lempet ut.
Fra dagens latterlig lave prising håper jeg den kan gå ytterligere 5-10 gangen etter det.
Absolutt muligheter, dersom cRNA blir så gullkantet som man kan håpe på.
1 Like
Giver vel ingen mening at lade Atlas vælge; de ønsker jo altid laveste kurs.
Men dessverre korrekt.
Circio ser da ut som en utmerket hedge for Invus innen RNA-feltet dersom investeringen i Laronde går over styr. Gapet mellom de respektive inngangsverdiene er jo som natt og dag.
Da bytter vi ut “boon for Laronde” med et annet kjent navn. Eh ?
4 Likes
“Party over” for Laronde ser det ut til.
Bull for Circio 
jo færre konkurrenter jo bedre.
ER denne aksjen nå ved turning-point.
Vi får se hva morgendagen bringer.
Tror vi kan få litt TG01 også - Kansas Cancer Center var på ASCO og hadde presentasjon av studien.
7 Likes
The inside story of how data integrity issues roiled a biotech seen as ‘Moderna 2.0’
By Allison DeAngelis — STAT and Ryan Cross — The Boston Globe
In February 2022, Diego Miralles, then-CEO of a buzzy new biotech called Laronde, gathered his employees in the company’s shiny new Somerville, Mass., headquarters to relay some unsettling news.
An internal investigation had uncovered a “bad assay” and poor note-taking in some of the core research being conducted at the company, Miralles told Laronde’s roughly 130 staffers. The incident was serious, he said, and the company needed to learn from it.
Though couched in careful language, his meaning was clear: There was a problem with some of Laronde’s key preclinical data.
It felt, one former staff member recalled, like all of the air had been sucked out of the room.
Miralles said one person was responsible for the issue, and though he didn’t say who, employees quickly connected the dots: Laronde had recently parted ways with one of its veteran scientists, a woman named Catherine Cifuentes-Rojas.
Cifuentes-Rojas had produced data for one of the company’s top drug candidates: an anti-obesity therapy that goes after the same hormone target as the blockbuster new weight loss drugs Wegovy and Mounjaro. It underpinned the enormous $440 million the biotech raised in a 2021 Series B funding round, according to four people with knowledge of its plans, as well as a slide from an internal slide deck, which valued the company at over $1 billion.
“Honestly, it was kind of shocking,” another former staff member said of Miralles’ announcement at the staff meeting. “As an employee, I was really worried. It’s not a good sign for a company.”
Over the following months, concerns over the integrity of the data have led to major tumult at Laronde, according to a STAT and Boston Globe investigation. The biotech shelved its two most advanced programs, including the GLP-1 therapy, and is likely to miss its internal goals of submitting paperwork for a clinical trial by the end of the year, three former employees said. Dozens of employees have left, as well as several top executives at the company.
For Laronde, which was founded by Flagship Pioneering — the ambitious startup-creating engine that bankrolled Moderna and countless other biotechs — the episode has highlighted how easy it can be to get carried away with the promise of new therapies, despite signs of trouble. Misgivings about the data had been circling for roughly a year before Miralles’ disclosure, according to three people, and many had tried and failed to replicate the stellar results that Cifuentes-Rojas had produced.
The exact nature of what occurred with Cifuentes-Rojas’ research is unclear to former employees. But there have been many hard-learned lessons at Laronde — once seen as “Moderna 2.0” by some employees — which should serve as an example for other biotechs, they said.
“She was presenting … data that was perfect. Anybody who works in in vivo [animal research] knows that’s not possible,” said Jane van Heteren, an ex-Laronde employee who worked on the same team as Cifuentes-Rojas.
Laronde declined a request for an interview. But in a lengthy statement, the company acknowledged that it had been developing a GLP-1 therapy throughout 2020 and 2021, but has since found that its early experiments were unreliable. “Certain individuals” involved in the GLP-1 work, it said, are no longer with the company.
“As always, we execute on our vision with high scientific rigor and standards, and if such standards are not adhered to, we act accordingly. As a clearer picture of our historic GLP-1 efforts emerged in 2022, we engaged our board and investors and took appropriate action,” the company said in the statement. “Those experiments do not bear on the prospects of our other platform applications.”
Cifuentes-Rojas did not respond to detailed questions sent to her home, her new employer, and an email address associated with her name.
This article is based on interviews with a dozen people with knowledge of the company’s inner workings and the people at the center of the investigation, which had not previously been disclosed. Most spoke under the condition of anonymity, out of fear of retribution from Flagship, or because they had signed agreements prohibiting them from discussing company matters.
Since Laronde’s inception, its executives have painted a picture of extraordinary possibilities.
The company was founded in 2017 to develop a new type of medicine, one that leverages RNA, the biological instruction manual used to make proteins. Specifically, Laronde’s focus was on what it called endless RNA.
Normally, cells make proteins using one form of RNA called messenger RNA, the same technology used by Moderna and BioNTech in their Covid vaccines. mRNA comes in the shape of a long strand. But that strand is fragile and difficult to work with, in part because of RNA-chomping enzymes called exonucleases that bite at the loose ends of linear mRNA and eat away at it.
Exonucleases make quick work of it: Most experts say that the mRNA used in the Covid vaccines is cleared from the body after a day or two. That burst of activity works for a vaccine, in which the goal is to make a protein that spurs an immune response. But it poses problems for drug developers hoping to use RNA to encode proteins for chronic therapies that need to be given for several months, years, or life.
By 2017, scientists at Laronde and elsewhere were converging on a novel idea: that by tying the loose ends of the RNA strand together into a ring of genetic information, it might be possible to create longer-lasting therapies that also trigger fewer immune system alarm bells. That could open up a new realm of possibilities for treating cancer, metabolic conditions, genetic diseases, and more.
(Former employees say that endless RNA is essentially equivalent to a technology called circular RNA, being developed by startups like Orna Therapeutics and Orbital Therapeutics. When asked what the differences were between the two technologies, Laronde Communications Director Marissa Hanify said “the technological similarities and/or differences are in the underlying sequences and elements,” but declined to give specific details).
Laronde thought this technology could produce scores of new drugs. At one point, executives gave employees T-shirts with a design of a cassette player on it, in reference to their belief that endless RNA was a plug-and-play system — pop in a new tape, and get a different output.
In public, company executives set an audacious goal of creating 100 new medicines by 2031.
People inside of Laronde believed the company’s longer-lasting RNA technology could help it supplant Moderna as the shining jewel in Flagship’s biotech collection. “We thought we were better, superior … Moderna on steroids,” one former executive said.
Even in the early days, there was pressure to back up the vision that management wanted to sell to the world, former employees said. This form of RNA was nascent, and in many ways, employees were on an exploration mission, figuring out how to best tie RNA into those microscopic loops and produce high-quality batches of the genetic material. Executives chafed at any negative results, though.
1 Like
"Strong interest from global pharma and specialist investors"
Akkurat det svadaet der har vi hørt i x antall år. Må snart bevises med avtaler eller synlig på aksjonærlistene for at det skal bety noe.
1 Like
God morgene Aune89 og Celestar.
Har dere stått opp med feil fot først?
Blir aldri noen god dag med å starte med slik surmuling.
Selg alle akjene i C, om dere har noen, og rett fokus og bruk energien på det dere har trua på.
1 Like
Dagens stalltips. Ny runde med bonds etter kosepraten. Det eneste av interesse er vel egentlig hvor mange. Citi nesten helt ute på siste liste og er sikkert helt tomme nå.
er enig med Holum,Circio er underprisa.Lite som skal til før vi får suksess på rett:)Men kjenner Atlas navnet har blitt ett skjelssord desverre
1 Like
Hva er knallsterkt egentlig? De oppdaterer med så og si ingenting nytt???
Er callen ferdig allerede??